PLG and neoplasm: Among these, the cyclo19,31[D-Cys19]-uPA19-31 was suggested as a promising possible drug in uPAR overexpressing tumor cells for its ability to inhibit uPA/uPAR interaction, disrupting uPA binding to uPAR and abrogating uPA plasminogen activation at the cell surface and fibrin degradation [105].